U.S. markets open in 3 hours 8 minutes
  • S&P Futures

    3,795.00
    -21.75 (-0.57%)
     
  • Dow Futures

    31,120.00
    -116.00 (-0.37%)
     
  • Nasdaq Futures

    12,589.25
    -92.50 (-0.73%)
     
  • Russell 2000 Futures

    2,185.60
    -20.20 (-0.92%)
     
  • Crude Oil

    60.95
    -0.33 (-0.54%)
     
  • Gold

    1,713.50
    -2.30 (-0.13%)
     
  • Silver

    25.96
    -0.43 (-1.62%)
     
  • EUR/USD

    1.2045
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.37
    +3.27 (+13.57%)
     
  • GBP/USD

    1.3935
    -0.0017 (-0.13%)
     
  • USD/JPY

    107.3410
    +0.3390 (+0.32%)
     
  • BTC-USD

    49,305.97
    -2,204.12 (-4.28%)
     
  • CMC Crypto 200

    988.65
    +1.44 (+0.15%)
     
  • FTSE 100

    6,609.60
    -65.87 (-0.99%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Return On Capital Employed Overview: Rigel Pharmaceuticals

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 sales of $16.02 million. Earnings fell to a loss of $17.39 million, resulting in a 182.71% decrease from last quarter. In Q1, Rigel Pharmaceuticals earned $21.03 million, and total sales reached $55.76 million.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Rigel Pharmaceuticals posted an ROCE of -0.28%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on RIGL

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Rigel Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.

For Rigel Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q2 Earnings Recap

Rigel Pharmaceuticals reported Q2 earnings per share at $-0.1/share, which beat analyst predictions of $-0.13/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.